The Helix system is actively being used, or has been used, in nine other clinical trials, including EXCELLENT (EXpanded CELL
ENdocardiac Transplantation), RECARDIO (Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy), and TRIDENT (TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis Study).
SAN CARLOS, Calif., September 15, 2014-CellProThera and BioCardia will collaborate partner on the EXCELLENT (Expanded Cell
Endocardiac Transplantation) Trial, a multi-center, controlled Phase l/2b study to evaluate the safety and efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand Automated Process and delivered via the BioCardia Helix Transendocardial Delivery System.